📊 ATRC Key Takeaways
Is AtriCure, Inc. (ATRC) a Good Investment?
AtriCure demonstrates strong product market fit with 14.9% revenue growth and exceptional 77.4% gross margins, but faces critical operational challenges with negative $7.8M free cash flow and interest coverage of only 0.3x. Despite excellent liquidity providing near-term runway, the disconnect between strong gross margins and collapsing profitability, combined with unsustainable cash burn, indicates fundamental business model stress that threatens long-term viability.
AtriCure shows strong fundamental improvement with nearly 15% revenue growth, very high 75.0% gross margins, and a sharp reduction in net losses, indicating progress toward sustainable profitability. The balance sheet is healthy, liquidity is strong, and positive operating cash flow plus free cash flow suggest the growth is supported by real cash generation rather than balance-sheet strain.
AtriCure, Inc. Key Strengths (ATRC)
- Robust revenue growth of 14.9% YoY demonstrates market demand
- Exceptional 77.4% gross margin reflects strong pricing power and manufacturing efficiency
- Fortress balance sheet with 4.29x current ratio and only 0.12x debt/equity ratio
- Strong cash reserves of $146.2M providing operational runway
- Revenue growth remains solid at 14.9% YoY, showing continued demand and business expansion
- Gross margin of 75.0% is exceptionally strong and provides room for future operating leverage
- Strong financial health with $167.43M in cash, low debt/equity of 0.13x, and positive free cash flow of $48.28M
ATRC Stock Risks: AtriCure, Inc. Investment Risks
- Negative operating cash flow of $4.0M and free cash flow of $7.8M despite positive net income signals severe operational distress
- Interest coverage ratio of 0.3x indicates inability to service $61.0M debt from operating earnings, creating refinancing risk
- Massive 77% gap between 77.4% gross margin and 0.4% operating margin suggests uncontrolled SG&A or operational expenses
- Near-zero profitability (0.1% net margin) leaves no margin for error in competitive medical device market
- The company is still unprofitable at the operating and net income level, so execution risk remains
- Negative interest coverage reflects weak earnings relative to financing costs despite low leverage
- Growth quality must continue to translate into durable margin expansion, not just higher revenue
Key Metrics to Watch
- Operating cash flow trend and path to positive conversion
- Interest coverage ratio improvement toward minimum 1.5x sustainability threshold
- Operating margin expansion to 5-10% range typical for medical device companies
- Working capital dynamics and cash conversion cycle efficiency
- Operating margin progression toward sustained positive profitability
- Free cash flow consistency alongside continued double-digit revenue growth
AtriCure, Inc. (ATRC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.29x current ratio provides a solid financial cushion.
ATRC Profit Margin, ROE & Profitability Analysis
ATRC vs Healthcare Sector: How AtriCure, Inc. Compares
How AtriCure, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AtriCure, Inc. Stock Overvalued? ATRC Valuation Analysis 2026
Based on fundamental analysis, AtriCure, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AtriCure, Inc. Balance Sheet: ATRC Debt, Cash & Liquidity
ATRC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AtriCure, Inc.'s revenue has grown significantly by 95% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.66 indicates the company is currently unprofitable.
ATRC Revenue Growth, EPS Growth & YoY Performance
ATRC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $123.6M | $108.0K | $0.00 |
| Q3 2025 | $115.9M | -$267.0K | $-0.01 |
| Q2 2025 | $116.3M | -$6.2M | $-0.13 |
| Q1 2025 | $108.9M | -$6.7M | $-0.14 |
| Q3 2024 | $98.3M | -$7.9M | $-0.17 |
| Q2 2024 | $100.9M | -$5.1M | $-0.11 |
| Q1 2024 | $93.5M | -$6.5M | $-0.14 |
| Q3 2023 | $83.2M | -$9.1M | $-0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AtriCure, Inc. Dividends, Buybacks & Capital Allocation
ATRC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AtriCure, Inc. (CIK: 0001323885)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 22, 2026 | 4 | xslF345X06/wk-form4_1779454631.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779295456.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779294824.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779285387.xml | View → |
| May 20, 2026 | 4 | xslF345X06/wk-form4_1779283537.xml | View → |
❓ Frequently Asked Questions about ATRC
What is the AI rating for ATRC?
AtriCure, Inc. (ATRC) has a Combined AI Grade of B from Claude (C) and ChatGPT (A) with 71% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ATRC's key strengths?
Claude: Robust revenue growth of 14.9% YoY demonstrates market demand. Exceptional 77.4% gross margin reflects strong pricing power and manufacturing efficiency. ChatGPT: Revenue growth remains solid at 14.9% YoY, showing continued demand and business expansion. Gross margin of 75.0% is exceptionally strong and provides room for future operating leverage.
What are the risks of investing in ATRC?
Claude: Negative operating cash flow of $4.0M and free cash flow of $7.8M despite positive net income signals severe operational distress. Interest coverage ratio of 0.3x indicates inability to service $61.0M debt from operating earnings, creating refinancing risk. ChatGPT: The company is still unprofitable at the operating and net income level, so execution risk remains. Negative interest coverage reflects weak earnings relative to financing costs despite low leverage.
What is ATRC's revenue and growth?
AtriCure, Inc. reported revenue of $141.2M.
Does ATRC pay dividends?
AtriCure, Inc. does not currently pay dividends.
Where can I find ATRC SEC filings?
Official SEC filings for AtriCure, Inc. (CIK: 0001323885) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ATRC's EPS?
AtriCure, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ATRC's fundamental grade?
Based on our AI fundamental analysis in June 2026, AtriCure, Inc. has a B grade with 71% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ATRC stock overvalued or undervalued?
Valuation metrics for ATRC: ROE of 0.0% (sector avg: 15%), net margin of 0.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ATRC's AI grade for 2026?
Our dual AI analysis gives AtriCure, Inc. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ATRC's free cash flow?
AtriCure, Inc.'s operating cash flow is $-4.0M, with capital expenditures of $3.9M. FCF margin is -5.6%.
How does ATRC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 0.1% (avg: 12%), ROE 0.0% (avg: 15%), current ratio 4.29 (avg: 2).